ESMO18 is rapidly approaching with only a week to go before the conference kicks off in Munich this year.

Munich

So far in our Preview series we have highlighted what to watch out for in the late breakers, neoantigens, as well as the oral talks and poster discussions.

Now it’s time to turn our focus on the nuggets or gems that can be gleaned from the poster halls – there’s always a few pleasant surprises in store. There are small and large pharma/biotech companies included in this latest list on a wide range of therapeutics and tumour types.

There are also some interesting emerging trends, as well as hints of what might happen with some future phase 3 readouts that could catch a few people by surprise.

To learn more from our latest assessment and get a heads up on our oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Posted by